baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. PUT 09/24 NOT/ DE000HD5HV70 /

2024-06-28 9:45:24 AM	Chg.0.0000	Bid2024-06-28	Ask2024-06-28	Underlying	Strike price	Expiration date	Option type
0.1300EUR	0.00%	0.1200 Bid Size: 35,000	0.1300 Ask Size: 35,000	Novartis AG	90.00 -	2024-09-18	Put

GlobeNewswire 06-27 XEALTH LAUNCHES DEWEY, THE INDUSTRY’S FIRST PERFORMANCE-BASED, DIGITAL HEALTH BENCHMARKING TOOL

GlobeNewswire 06-26 As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...

GlobeNewswire 06-13 Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment

GlobeNewswire 05-29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

TeleTrader 05-02 Novartis to acquire Mariana Oncology for $1.7B

TeleTrader 04-23 Novartis up 5% on upbeat guidance, earnings

TeleTrader 04-23 Novartis EPS up 28% to $1.31 in Q1

GlobeNewswire 04-16 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...

TeleTrader 04-11 Novartis launches offer for Morphosys at €68 per share

TeleTrader 04-09 Novartis to reduce workforce by 680 in Product Development

GlobeNewswire 03-14 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon

TeleTrader 03-12 Germany clears Novartis' MorphoSys $2.9B deal

GlobeNewswire 02-28 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

TeleTrader 02-05 Novartis to acquire MorphoSys for $2.9B

TeleTrader 01-31 Novartis net sales up 8% to $11.4B in Q4

GlobeNewswire 01-10 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...

GlobeNewswire 01-05 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...

GlobeNewswire 01-02 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...

GlobeNewswire 2023-12-21 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...

GlobeNewswire 2023-12-19 Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...

GlobeNewswire 2023-12-11 Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...

GlobeNewswire 2023-12-08 Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...

GlobeNewswire 2023-12-06 Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...

TeleTrader 2023-11-28 Novartis expects 5% annual sales growth until 2027

GlobeNewswire 2023-11-20 Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH

UC WAR. PUT 09/24 NOT/ DE000HD5HV70 /

If you wish to receive reply to your feedback, please provide your email address.